SG11201912651WA - New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it - Google Patents
New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing itInfo
- Publication number
- SG11201912651WA SG11201912651WA SG11201912651WA SG11201912651WA SG11201912651WA SG 11201912651W A SG11201912651W A SG 11201912651WA SG 11201912651W A SG11201912651W A SG 11201912651WA SG 11201912651W A SG11201912651W A SG 11201912651WA SG 11201912651W A SG11201912651W A SG 11201912651WA
- Authority
- SG
- Singapore
- Prior art keywords
- diethylphenyl
- ino
- pyrazolo
- quinazoline
- piperidin
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305826 | 2017-06-29 | ||
| PCT/EP2018/067394 WO2019002454A1 (en) | 2017-06-29 | 2018-06-28 | NOVEL N- (2,6-DIETHYLPHENYL) -8 - ({4- [4- (DIMETHYLAMINO) PIPERIDIN-1-YL] -2-METHOXYPHENYL} AMINO) -1-METHYL-4,5-DIHYDRO-1H SALT -PYRAZOLO [4,3-H] QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION AND FORMULATIONS CONTAINING THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912651WA true SG11201912651WA (en) | 2020-01-30 |
Family
ID=59313166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912651WA SG11201912651WA (en) | 2017-06-29 | 2018-06-28 | New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11160806B2 (enExample) |
| EP (1) | EP3645535B1 (enExample) |
| JP (1) | JP7141416B2 (enExample) |
| KR (1) | KR102609333B1 (enExample) |
| CN (1) | CN110896636B (enExample) |
| AR (1) | AR112040A1 (enExample) |
| AU (1) | AU2018293729B9 (enExample) |
| CA (1) | CA3068357C (enExample) |
| CL (1) | CL2019003848A1 (enExample) |
| EA (1) | EA039764B1 (enExample) |
| ES (1) | ES2900048T3 (enExample) |
| IL (1) | IL271628B2 (enExample) |
| MA (1) | MA49498A (enExample) |
| PL (1) | PL3645535T3 (enExample) |
| SG (1) | SG11201912651WA (enExample) |
| TW (1) | TWI750393B (enExample) |
| UY (1) | UY37778A (enExample) |
| WO (1) | WO2019002454A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025002962A1 (en) | 2023-06-30 | 2025-01-02 | Nerviano Medical Sciences S.R.L. | Use of a mps1 inhibitor for the treatment of hepatocellular carcinoma |
| WO2025021587A1 (en) | 2023-07-21 | 2025-01-30 | Nerviano Medical Sciences S.R.L. | Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2303891B1 (en) * | 2008-06-26 | 2016-02-17 | Les Laboratoires Servier | Pyrazolo-quinazolines as protein kinase activity modulators |
-
2018
- 2018-06-21 UY UY0001037778A patent/UY37778A/es not_active Application Discontinuation
- 2018-06-28 EP EP18732820.8A patent/EP3645535B1/en active Active
- 2018-06-28 CA CA3068357A patent/CA3068357C/en active Active
- 2018-06-28 TW TW107122235A patent/TWI750393B/zh active
- 2018-06-28 KR KR1020207002339A patent/KR102609333B1/ko active Active
- 2018-06-28 ES ES18732820T patent/ES2900048T3/es active Active
- 2018-06-28 JP JP2019572116A patent/JP7141416B2/ja active Active
- 2018-06-28 AU AU2018293729A patent/AU2018293729B9/en active Active
- 2018-06-28 AR ARP180101781A patent/AR112040A1/es unknown
- 2018-06-28 MA MA049498A patent/MA49498A/fr unknown
- 2018-06-28 US US16/624,488 patent/US11160806B2/en active Active
- 2018-06-28 EA EA202090115A patent/EA039764B1/ru unknown
- 2018-06-28 CN CN201880043442.0A patent/CN110896636B/zh active Active
- 2018-06-28 WO PCT/EP2018/067394 patent/WO2019002454A1/en not_active Ceased
- 2018-06-28 PL PL18732820T patent/PL3645535T3/pl unknown
- 2018-06-28 SG SG11201912651WA patent/SG11201912651WA/en unknown
-
2019
- 2019-12-22 IL IL271628A patent/IL271628B2/en unknown
- 2019-12-26 CL CL2019003848A patent/CL2019003848A1/es unknown
-
2021
- 2021-09-30 US US17/490,318 patent/US20220016122A1/en not_active Abandoned
-
2024
- 2024-07-01 US US18/760,494 patent/US20240350501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201904971A (zh) | 2019-02-01 |
| CL2019003848A1 (es) | 2020-07-10 |
| CA3068357C (en) | 2022-04-19 |
| US11160806B2 (en) | 2021-11-02 |
| UY37778A (es) | 2019-01-31 |
| AU2018293729A1 (en) | 2020-01-23 |
| CA3068357A1 (en) | 2019-01-03 |
| US20220016122A1 (en) | 2022-01-20 |
| US20240350501A1 (en) | 2024-10-24 |
| AR112040A1 (es) | 2019-09-11 |
| PL3645535T3 (pl) | 2022-03-21 |
| BR112019027924A2 (pt) | 2020-08-18 |
| TWI750393B (zh) | 2021-12-21 |
| IL271628A (en) | 2020-02-27 |
| IL271628B2 (en) | 2023-07-01 |
| EP3645535A1 (en) | 2020-05-06 |
| KR102609333B1 (ko) | 2023-12-01 |
| JP2020525477A (ja) | 2020-08-27 |
| MA49498A (fr) | 2021-05-26 |
| EP3645535B1 (en) | 2021-09-08 |
| EA039764B1 (ru) | 2022-03-11 |
| IL271628B1 (en) | 2023-03-01 |
| CN110896636B (zh) | 2022-07-19 |
| AU2018293729B2 (en) | 2022-03-10 |
| AU2018293729B9 (en) | 2022-07-14 |
| US20200246339A1 (en) | 2020-08-06 |
| JP7141416B2 (ja) | 2022-09-22 |
| KR20200020905A (ko) | 2020-02-26 |
| WO2019002454A1 (en) | 2019-01-03 |
| EA202090115A1 (ru) | 2020-05-25 |
| CN110896636A (zh) | 2020-03-20 |
| ES2900048T3 (es) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289763A (en) | Compounds, pharmaceutical compounds and methods for preparing compounds and their use | |
| IL273852A (en) | Preparation and storage of liposomal RNA formulations suitable for treatment | |
| IL267210A (en) | Amino acid compounds and methods for treating muscle diseases and disorders | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| EP3250572A4 (en) | Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | |
| IL281924A (en) | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making | |
| HUE043122T2 (hu) | Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk | |
| WO2016065028A8 (en) | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| PL3697784T3 (pl) | Związki imidazo[4,5-b]pirydyny i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych | |
| ZA201708429B (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| PL3661508T3 (pl) | Sposób wytwarzania doustnej postaci dawkowania zawierającej berberynę, doustna postać dawkowania zawierająca berberynę i jej zastosowanie | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| IL271628A (en) | A new salt of N-(6,2-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-5,4-dihydro-1H -pyrazolo[3,4-H]quinazoline-3-carboxamide, its preparation and formulations containing it | |
| IL265153A (en) | 8-(azetidin-1-yl)-[4,2,1]triazolo[5,1-a]pyridinyl compounds, preparations and methods of use | |
| PT3398946T (pt) | Sal de derivado de morfolina e a sua forma cristalina, bem como método de preparação, composição farmacêutica e a sua utilização | |
| WO2017075264A8 (en) | Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders | |
| GB201918401D0 (en) | Novel crystalline forms of Flufenacet, methods for their preparation and use of the same | |
| GB201918391D0 (en) | Novel crystalline forms of flufenacet, methods for their preparation and use of the same | |
| HK40103521A (zh) | 1，1-二甲双胍的亚硝酸盐、药物组合物和使用方法 | |
| HK40103021A (zh) | 1，1-二甲双胍的亚硝酸盐、药物组合物和使用方法 | |
| EA201790795A1 (ru) | СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА |